Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc.'s Q·Score is 5.7/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.3× debt-to-equity). Key area to monitor: currently unprofitable (-143% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for RCUS is $34.00, based on ratings from 10 Wall Street analysts. This is 32.4% above the current price of $25.68. Price targets are forward-looking estimates and not guarantees of future performance.

Arcus Biosciences, Inc. (RCUS) scores in line with sector averages on valuation metrics. The consensus analyst price target of $34.00 is 32% above the current price.

Arcus Biosciences, Inc. is scheduled to report earnings in 2 days, on May 5, 2026.

Arcus Biosciences, Inc. has a net profit margin of -142.9%, indicating the company is currently operating at a net loss. Its gross margin stands at -111.7%, reflecting a more cost-intensive business model.

Arcus Biosciences, Inc. is reporting strong year-over-year growth of 26.9%.

Arcus Biosciences, Inc. has a debt-to-equity ratio of 0.35×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 4.36×, indicating comfortable short-term liquidity.